Evidence map›Paper›PMID 31300338›Full record

ArticleClinical breast cancer2019

Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.

Devon Livingston-Rosanoff, Jessica Schumacher, Kara Vande Walle, Trista Stankowski-Drengler, Caprice C Greenberg, Heather Neuman, Lee G Wilke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Devon Livingston-RosanoffDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI. Electronic address: livingstonrosanoff@surgery.wisc.edu.
Jessica SchumacherWisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI.
Kara Vande WalleDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI.
Trista Stankowski-DrenglerDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI.
Caprice C GreenbergDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI.
Heather NeumanDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI; Wisconsin Institute for Surgical Outcomes Research, Department of Surgery, University of Wisconsin, Madison, WI.
Lee G WilkeDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI.

Funding

UW Surgical Oncology Research Training Program (UW-SORT)T32CA090217 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Muhammed Murtaza, Heather B Neuman · 2001 to 2026
$8.3M
NCI NIH HHS T32 CA090217
6 · The paper itself

Abstract

backgroundTumor size has historically been used to stage breast cancer and guide treatment recommendations. The importance of tumor biology in long-term outcomes is increasingly being acknowledged. No large studies have examined the relative roles of tumor size and receptor status on response to neoadjuvant chemotherapy (NAC) in breast cancer. PATIENTS AND

methodsThe National Cancer Database was queried for women who underwent NAC and surgery for unilateral clinical stage I to III (cT1-3) invasive breast cancer from 2010 to 2013. Multivariable logistic regression models were used to assess the relation between receptor status, tumor size, and pathologic complete response (pCR) while controlling for other biologic, sociodemographic, diagnosis, and treatment factors.

resultsWe included 38,864 women in this study, most presented with cT2 disease (55%). Patients predominantly had estrogen receptor (ER)/progesterone receptor (PR)-positive (ER/PR

conclusionTumor size is independently associated with pCR after NAC after controlling for receptor status, although the effect of receptor status is stronger. These data reinforce the importance of receptor status as well as tumor size, each of which might act as surrogates for tumor biology, in setting expectations for outcomes in patients who undergo NAC.

Indexed as

Tumor BurdenAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneComplete pathologic responseNACNational Cancer DatabaseNCDBTNM staging

Identifiers

PMID31300338
PMCPMC6888946

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.